stockrowOcular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024.
- Revenue
- +0.12%
- EPS
- +10.3%
- Free cash flow
- −25.4%
- Total debt
- +4.13%
Quarter to June 2026, against a year earlier
Follow OCUL
Alert me
Ocular Therapeutix, Inc. (OCUL) EV/Sales
As of 6 November 2026, Ocular Therapeutix, Inc. (OCUL) trades at a EV/Sales of 18.5×. Over the past ten years it has ranged from 2.2× (November 2023) to 719× (March 2015); the current reading is higher than 30% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 30.9× | 91.79% |
| FY2024 | 16.1× | 258.57% |
| FY2023 | 4.5× | 39.40% |
| FY2022 | 3.2× | (66.54%) |
| FY2021 | 9.6× | (84.33%) |
| FY2020 | 61.5× | 49.72% |
| FY2019 | 41.1× | (33.20%) |
| FY2018 | 61.5× | 7.99% |
| FY2017 | 57.0× | (29.47%) |
| FY2016 | 80.8× | 10.43% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 32.3× | 29.09% |
| Mar 2026 | 25.0× | (19.04%) |
| Dec 2025 | 30.9× | (7.99%) |
| Sep 2025 | 33.6× | 48.81% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.6× |
| ANAB AnaptysBio, Inc. compare | 4.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.3× |
| OCUL Ocular Therapeutix, Inc. | 18.5× |
| QURE uniQure N.V. compare | 44.7× |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)